InnAccel Technologies: Indian MedTech Designed for the Hardest Clinical Environments

Advanced medical equipment is usually designed around an assumption: a hospital will have dependable electricity, compressed-air systems, trained specialists, sophisticated intensive-care infrastructure and easy access to maintenance.

Across much of India and other emerging markets, those assumptions do not always hold.

Bengaluru-based InnAccel Technologies has built its medical-device strategy around this gap. Rather than taking equipment created for highly equipped Western hospitals and simply reducing its price, the company identifies clinical problems inside Indian hospitals and develops devices specifically around the conditions in which doctors and nurses actually work.

Its portfolio now includes SAANS, an infrastructure-independent breathing-support system for newborns and infants; Fetal Lite, an AI-assisted wireless fetal-monitoring platform; and VAPCARE, an automated system designed to improve secretion management and oral hygiene for mechanically ventilated patients.

Together, the devices represent an increasingly important dimension of India’s Make in India programme: medical technology designed in India for clinical environments where reliability, portability and simplicity can be as important as sophistication.

Starting with Problems Inside Indian Hospitals

InnAccel began its medical-device development programme in 2014.

Instead of beginning with a predetermined technology, the company says its teams entered partner hospitals and conducted what it describes as deep clinical immersion. Engineers worked alongside healthcare professionals to identify problems that existing medical equipment did not adequately solve.

By 2015, InnAccel had launched its Product Engineering and Development platform and started working on the three highest-priority problems identified through this process. In 2019, the company launched its three core medical technologies in India after development, testing and intellectual-property work.

This clinical-first approach is significant.

A medical device can be technically excellent and still fail in a rural or district hospital if it needs infrastructure the hospital does not possess. Equipment that requires specialised installation, continuous electrical supply or highly trained operators can become difficult to use outside major medical centres.

InnAccel’s products therefore place considerable emphasis on portability, automation, digital monitoring and reduced dependence on supporting infrastructure.

SAANS: Breathing Support Without a Conventional NICU Setup

Among InnAccel’s best-known technologies is SAANS, developed to provide non-invasive breathing support to newborns and paediatric patients.

Premature and critically ill babies can suffer from respiratory distress syndrome, in which immature lungs struggle to provide sufficient oxygen. Continuous Positive Airway Pressure, or CPAP, can help keep the airways and lungs open while the child continues breathing spontaneously.

Conventional neonatal CPAP systems are commonly associated with neonatal intensive-care units equipped with compressed medical gases, reliable power and specialised staff.

SAANS was designed to make this therapy more accessible.

The system incorporates its own air source or flow generator and can work with different oxygen sources, including a central oxygen line, cylinder or concentrator. It also has an internal battery, digital monitoring and alarms. InnAccel’s current platform supports Bubble CPAP, nasal CPAP, high-flow nasal cannula therapy and resuscitation modes.

That infrastructure independence is particularly important when transporting babies between hospitals or when treating patients at facilities without a fully equipped neonatal intensive-care unit.

The World Health Organization included SAANS in its 2022 Compendium of Innovative Health Technologies for Low-Resource Settings, describing it as an Indian-origin, infrastructure-independent breathing-support system with an internal flow generator, air-oxygen blending, battery backup and digital controls.

More Than 2,000 SAANS Systems Deployed

InnAccel says more than 2,000 SAANS devices have been deployed across India.

One significant deployment took place in Assam, where InnAccel and Bengaluru’s Centre for Cellular and Molecular Platforms, or C-CAMP, implemented a state-wide programme supported by USAID and the Bill & Melinda Gates Foundation.

The objective was to bring neonatal respiratory support into healthcare environments where access to conventional neonatal intensive-care infrastructure remained limited.

The project illustrates the larger purpose behind the technology.

SAANS is not simply a smaller CPAP machine. Its design attempts to move a therapy normally concentrated in advanced hospitals further down the healthcare system, including facilities that may need to stabilise a newborn before transferring the child to a specialist centre.

For a country with enormous geographical variation in healthcare access, this capability can be particularly valuable.

SAANS Receives US FDA Clearance

The platform reached another important milestone in January 2026, when the US Food and Drug Administration granted SAANS 510(k) clearance.

FDA records identify the device as K251165 and classify it as a Class II non-invasive positive-airway-pressure system. The agency cleared SAANS for providing CPAP support to spontaneously breathing neonates and infants weighing up to 10 kilograms who require respiratory assistance, including babies affected by conditions associated with prematurity such as respiratory distress syndrome.

The FDA indication specifically covers use in hospital environments.

The clearance represents more than an export opportunity. For an Indian-designed neonatal respiratory device to pass through the US regulatory process demonstrates that medical technologies originally developed around healthcare challenges in emerging markets can also meet regulatory requirements in advanced markets.

Fetal Lite: Using AI to Improve Fetal Monitoring

InnAccel’s second major platform tackles another clinical challenge: identifying fetal distress during pregnancy and labour.

Hospitals traditionally monitor fetal heart rate using cardiotocography and Doppler-based systems. These systems can require skilled positioning of sensors, repeated adjustment when the fetus moves and relatively bulky equipment.

InnAccel developed Fetal Lite as a portable and wireless alternative.

The platform uses ECG and EMG signal extraction technology to monitor fetal and maternal physiological signals. For mothers beyond 36 weeks of pregnancy, one configuration uses a single probe to obtain fetal heart rate, maternal heart rate and uterine activity.

The device incorporates digital storage, remote access and an AI-driven risk-classification system intended to help identify patterns associated with fetal distress.

Rather than replacing the obstetrician, the AI component is intended to assist clinicians by analysing monitoring data and highlighting cases that may require closer attention.

Designed for Places Without Continuous Specialist Supervision

Portability becomes especially valuable in maternal healthcare because a woman requiring fetal assessment may not always be located near a tertiary hospital.

Fetal Lite is wireless and comparatively compact. The company says its system automatically recalibrates when fetal movement occurs and can store monitoring information digitally for remote review.

Such features could allow fetal monitoring to extend beyond major obstetric centres into smaller hospitals, mobile medical units and other healthcare settings.

InnAccel reports that one deployment placed Fetal Lite aboard a Mobile Medical Unit serving 18 villages and approximately 2,300 members of a tribal community. According to the company, the system had conducted more than 300 scans and detected 12 cases of fetal distress that led to referral for higher-level treatment.

These figures come from InnAccel’s own programme reporting, but they demonstrate the type of environment for which the technology was designed.

Indian Intellectual Property Behind Fetal Lite

The device also contains intellectual property developed within India.

InnAccel says the Government of India granted it a patent in 2024 covering proprietary medical-electrode technology used in Fetal Lite.

The platform had earlier won the Global Women’s HealthTech Award at CES in 2021, while InnAccel lists Indian CDSCO and European CE regulatory credentials for its current Fetal Lite system.

In 2026, the company also reported that the technology had received recognition from the Gates Foundation as a potential breakthrough technology for reducing maternal and intrapartum mortality.

For India’s medtech sector, the importance lies in developing not only the physical monitor but also the signal-processing algorithms, sensors, software and clinical intelligence behind it.

VAPCARE Targets a Dangerous ICU Complication

InnAccel’s third major platform addresses a very different clinical environment: the intensive-care unit.

Patients who remain on mechanical ventilation for extended periods face the risk of ventilator-associated pneumonia, or VAP.

Secretions can accumulate around a patient’s mouth, throat and breathing tube. Nurses and other healthcare workers therefore perform regular oral hygiene and suctioning procedures to reduce infection risk.

These procedures are essential but highly dependent on consistent manual execution.

InnAccel developed VAPCARE to automate parts of this process.

The company describes the system as an automated and intelligent platform for secretion clearance and oral hygiene management in mechanically ventilated patients. It can perform automated suction from the oropharyngeal and subglottic regions, conduct oral lavage and adjust suction according to sensor feedback.

Users can configure suction pressure and frequency according to a patient’s requirements.

By automating repetitive aspects of care, VAPCARE aims to improve adherence to infection-control protocols while reducing the amount of time healthcare workers spend performing manual suctioning procedures.

Automation Where Healthcare Workers Are Stretched

The significance of VAPCARE becomes clearer when considered in the context of busy intensive-care units.

A device that automates routine but important processes does not merely save labour. It can help make care more consistent when staff are treating many critically ill patients simultaneously.

InnAccel says VAPCARE can detect and clear blockages in its suction ports while using sensors to limit suction duration and reduce the risk of tissue injury.

During the COVID-19 pandemic, the company conducted pilot use of the device and reported reductions in caregiver-patient interaction and bedside time compared with conventional manual care. A larger 420-patient clinical study at Narayana Health in Bengaluru is examining whether the technology can reduce ventilator-associated pneumonia and antibiotic requirements compared with standard practice.

As with any medical device undergoing continuing clinical evaluation, larger studies are important for establishing the magnitude of its benefits.

Responding to the COVID-19 Emergency

InnAccel also adapted its respiratory technology during the COVID-19 pandemic.

Using the SAANS platform as a starting point, the company developed SAANS Pro, combining high-flow nasal cannula and CPAP capabilities for adults, along with a CPAP helmet.

InnAccel says more than 600 SAANS Pro systems and around 6,000 helmets were deployed to more than 60 government hospitals and COVID centres across India over approximately 18 months. Many were supplied through programmes supported by ACT Grants and the American India Foundation.

The episode demonstrated another advantage of maintaining indigenous engineering capability.

When a national health emergency creates sudden demand for medical equipment, domestic teams can modify existing technology, manufacture new configurations and respond to local clinical requirements more rapidly than a healthcare system entirely dependent on imports.

WHO Recognition for Low-Resource Medical Technology

InnAccel’s development philosophy has received international recognition because it addresses a problem that extends far beyond India.

Billions of people live in countries where modern healthcare technology exists but remains concentrated in major cities and tertiary hospitals.

The WHO’s low-resource health-technology programme evaluates technologies intended to operate under such conditions. Its assessments consider clinical performance, regulatory requirements, technical specifications, health-technology management and the feasibility of local production.

InnAccel says both SAANS and VAPCARE were included in the WHO’s 2022 Compendium of Innovative Technologies for Low-Resource Settings, while SAANS appears in the WHO’s published assessment as an Indian-origin neonatal CPAP technology.

This international interest reflects a broader opportunity for Indian medical-device companies.

Products engineered for India’s constraints can also be highly relevant across Africa, Southeast Asia, Latin America and other regions confronting similar infrastructure challenges.

Engineering Around Constraints Instead of Ignoring Them

One of the most interesting aspects of InnAccel’s work is that infrastructure constraints become part of the engineering specification.

For SAANS, that means internal airflow generation, battery operation and compatibility with different oxygen supplies.

For Fetal Lite, it means portability, wireless monitoring, automatic signal processing and remote access.

For VAPCARE, it means automating a labour-intensive ICU procedure and reducing dependence on continuous manual intervention.

These are not simply features added after development. They address the environments in which the technologies are expected to operate.

That represents an important shift in Indian medical-device engineering.

For decades, much of India’s healthcare system depended on equipment originally designed around the requirements of hospitals in wealthier countries. Indian companies increasingly have the opportunity to start with domestic clinical problems and engineer technology from the ground up.

From Imported Equipment to Indian Medical Intellectual Property

India is already one of the world’s largest producers of medicines and vaccines, but the country’s dependence on imported high-value medical devices has historically remained much greater.

Building indigenous medical-device capability therefore requires more than manufacturing plastic components or assembling imported electronics.

India needs companies capable of identifying clinical problems, developing intellectual property, engineering hardware, creating embedded software and AI algorithms, conducting trials, obtaining regulatory approvals and scaling manufacturing.

InnAccel’s development trajectory touches most of these stages.

The company says it had already launched three core technologies backed by global patents by 2019. Its portfolio now holds Indian and international regulatory approvals, while SAANS has progressed as far as US FDA clearance in 2026.

This is the deeper form of localisation required if India wants to become not only a medical-device manufacturing base but also a source of new healthcare technology.

Building Devices for India — and the World

InnAccel Technologies represents a distinctive version of the Make in India story.

Its products are not designed primarily around convenience for already well-equipped hospitals. They are built around difficult clinical environments where power may fail, specialised equipment may be unavailable, trained healthcare workers may be stretched and the nearest tertiary hospital may be hours away.

SAANS attempts to take neonatal respiratory support beyond the conventional NICU.

Fetal Lite uses portable sensors, digital connectivity and artificial intelligence to make fetal monitoring easier to deploy.

VAPCARE applies automation to one of the repetitive but crucial infection-control tasks inside intensive-care units.

Each solves a different medical problem, yet all three share the same engineering philosophy: advanced medical care should not depend entirely on advanced infrastructure.

That philosophy gives InnAccel’s technology relevance far beyond India.

Emerging markets contain much of the world’s future healthcare demand. Companies capable of creating reliable medical equipment for these environments could address a global market that traditional high-cost medical-device manufacturers have often struggled to serve.

In this sense, InnAccel is doing more than replacing imported medical machines.

It is demonstrating that India can design medical technology around problems that affect hundreds of millions of people — and potentially turn solutions created for Indian hospitals into globally relevant healthcare products.

---